CN1579544A - Sucking tablet for promoting liver cell to growth - Google Patents
Sucking tablet for promoting liver cell to growth Download PDFInfo
- Publication number
- CN1579544A CN1579544A CN 03143959 CN03143959A CN1579544A CN 1579544 A CN1579544 A CN 1579544A CN 03143959 CN03143959 CN 03143959 CN 03143959 A CN03143959 A CN 03143959A CN 1579544 A CN1579544 A CN 1579544A
- Authority
- CN
- China
- Prior art keywords
- hepatocyte growth
- buccal tablet
- promoting factors
- tablet according
- hgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000005229 liver cell Anatomy 0.000 title abstract 3
- 230000001737 promoting effect Effects 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 claims abstract description 13
- 239000000872 buffer Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000000945 filler Substances 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- 229940046011 buccal tablet Drugs 0.000 claims description 20
- 239000006189 buccal tablet Substances 0.000 claims description 20
- 210000003494 hepatocyte Anatomy 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000001962 taste-modifying agent Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 2
- 108010039627 Aprotinin Proteins 0.000 claims description 2
- 108010001478 Bacitracin Proteins 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004405 aprotinin Drugs 0.000 claims description 2
- 229960003071 bacitracin Drugs 0.000 claims description 2
- 229930184125 bacitracin Natural products 0.000 claims description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 229940027278 hetastarch Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229960004025 sodium salicylate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000007935 oral tablet Substances 0.000 abstract 1
- 229940096978 oral tablet Drugs 0.000 abstract 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 25
- 239000000203 mixture Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention is an oral medicine tablet for advancing liver cell growth. Its ingredients and contents are: liver cell growth advancing element 0.05-15%, filler 50-99.9%, stabilizer 0.05-30%, absorption advancer 0-30%, taste modifier 0-20%, pH value buffer 0-25%, HGF element in the oral tablet has a good stability, the taste is well, and it is convenient, and it is easy to be absorbed by mouth mucous.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of pharmaceutical preparation of buccal absorption of hepatocyte growth-promoting factors.
Background technology
Hepatocyte growth-promoting factors (Hepatocyte Growth Factor, be called for short HGF) be a kind of can the synthetic polypeptides matter of cell cultured supernatant DNA, be called hepatocyte growth factor, hepatic cell growth stimulating factor etc. again, normally obtain from animal livers (as the piglets liver) extraction and the production of genetic engineering recombination method.Hepatocyte growth-promoting factors (HGF) is at aspect determined curative effects such as treatment hepatitis, hepatic injury and hepatic fibrosis, because the oral meeting of HGF is destroyed its biological activity by digestive enzyme, influence therapeutic effect, the HGF that uses clinically all is injections at present, and patient especially chronic patients life-time service is very inconvenient.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical preparation of the hepatocyte growth-promoting factors that absorbs by buccal, its can be fine maintenance HGF active and absorb the effect that reaches the treatment disease by oral cavity and hypoglossis mucous membrane, have easy to use, be easy to be accepted and advantage such as compliance is good by the patient.
In order to achieve the above object, the solution that the present invention adopts is: hepatocyte growth-promoting factors is made buccal tablet, make it be easy to dissolve and discharge the absorption of HGF through port transmucosal under the effect of saliva of buccal cavity.
Concrete component design of the present invention and content are (weight percent content):
Hepatocyte growth-promoting factors 0.05～15%, filler 50～99.9%, stabilizing agent 0.05～30%, absorption enhancer 0～30%, taste modifying agent 0～20%, pH value buffer agent 0～25%.
Filler is the pharmaceutic adjuvant that is used for diluting and absorb HGF, is convenient to bind tabletting shaping and buccal absorption, selects one or more combinations in starch, starch slurry, dextrin, mucialga of arabic gummy, gelatine size, Icing Sugar, lactose, the Polyethylene Glycol for use;
Stabilizing agent is to be used for protecting HGF stable existence and avoid reducing its active pharmaceutic adjuvant in buccal tablet, selects one or more combinations in lysine, arginine, glutamic acid, histidine, hetastarch, hydroxymethyl starch, low molecular dextran, mannitol, sorbitol, xylitol, sodium chloride and the polyvidon for use;
Absorption enhancer has and promotes the absorption of HGF in oral mucosa, suppresses the oral mucosa endoenzyme, prevents that HGF is by the effect of enzyme hydrolysis in the oral mucosa, absorption enhancer is selected one or more combinations in sodium laurylsulfate, sodium deoxycholate, aprotinin, propylene glycol, azone, menthol, bacitracin, NaGC, the sodium salicylate for use, absorption enhancer in containing slice prescription available also can, when its content is 0, represent without this composition;
The taste modifying agent is to improve the flavouring quality of medicine when containing to be convenient to the happy pharmaceutic adjuvant of accepting and using of patient, select one or more combinations in menthol, Borneolum Syntheticum, cyclamate, glycyrrhizin, the citric acid for use, the taste modifying agent in containing slice prescription available also can, when its content is 0, represent without this composition;
The pH value buffer agent is to regulate buccal tablet dissolve back pH value in the oral cavity variation, selects a kind of or its combination in phosphate, the citrate for use, the pH value buffer agent in containing slice prescription available also can, when its content is 0, represent without this composition.
Should be noted that the absorption enhancer in the HGF buccal tablet of the present invention, taste modifying agent and pH value buffer agent can exist simultaneously or not be present in the drug formulation of buccal tablet, also can be in wherein a kind of drug formulation that is present in buccal tablet.
Should be noted that simultaneously, not only comprise the HGF of the various molecular weight that extract and produce by genetic engineering from animal livers, also comprise the chemical modification body of acceptable HGF on the medicine as the HGF in the HGF troche of the present invention.
In addition, it will be appreciated by those skilled in the art that the manufacture method of HGF buccal tablet of the present invention is similar to conventional medicine tablet manufacture method, repeats no more here.
Because HGF buccal tablet of the present invention adopts above-mentioned formula system, the good stability of HGF composition not only, features good taste, and suck and absorb easy to usely, be easy to oral mucosa and absorb.
The specific embodiment
Embodiment 1. gets HGF dry powder 4 grams, lysine 10 grams, lactose 900 grams, Icing Sugar 380 grams, starch slurry (17%) 1000 gram.
It is stand-by earlier HGF and lysine and 50 to be restrained the lactose mix homogeneously.With the starch slurry mix homogeneously of 850 gram lactose, 380 gram Icing Sugar, 1000 grams, granulation, drying are made blank granule, to stand-by HGF mixture and the abundant mixing of blank gradation of mixing again, tabletting promptly makes every weight at 0.5～0.8 gram, detects packing and gets final product.
Embodiment 2. adds 70 gram menthols in the composition of embodiment 1, earlier menthol and lactose, Icing Sugar, starch slurry are made blank granule, again with the mixture mixing tabletting of HGF, lysine and lactose, promptly makes the HGF buccal tablet of Herba Menthae taste.
Embodiment 3. gets HGF dry powder 10 grams, arginine 15 grams, sodium laurylsulfate 80 grams, starch 1500 grams, dextrin 210 grams, Icing Sugar 220 grams, 800 milliliters of 0.02M phosphate buffer aqueous solutions (PH=5.5).
Earlier HGF dry powder, arginine, sodium laurylsulfate are dissolved in respectively in 800 ml phosphate buffers and make mixed solution, mixing is stand-by.Again starch, dextrin, Icing Sugar are mixed into uniform powder, then mixed solution are sprayed in mixed-powder, stir, tabletting gets final product after granulation, the cold drying.
Claims (8)
1. the hepatocyte growth-promoting factors buccal tablet is characterized in that the each component of medicine and content thereof are as follows: hepatocyte growth-promoting factors 0.05～15%, filler 50～99.9%, stabilizing agent 0.05～30%, absorption enhancer 0～30%, taste modifying agent 0～20%, pH value buffer agent 0～25%.
2. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that filler selects one or more combinations in starch, starch slurry, dextrin, mucialga of arabic gummy, gelatine size, Icing Sugar, lactose, the Polyethylene Glycol for use.
3. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that stabilizing agent selects one or more combinations in lysine, arginine, glutamic acid, histidine, hetastarch, hydroxymethyl starch, low molecular dextran, mannitol, sorbitol, xylitol, sodium chloride and the polyvidon for use.
4. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that absorption enhancer selects one or more combinations in sodium laurylsulfate, sodium deoxycholate, aprotinin, propylene glycol, azone, menthol, bacitracin, NaGC, the sodium salicylate for use;
5. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that the taste modifying agent selects one or more combinations in menthol, Borneolum Syntheticum, cyclamate, glycyrrhizin, the citric acid for use.
6. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that the pH value buffer agent selects a kind of or its combination in phosphate, the citrate for use.
7. hepatocyte growth-promoting factors buccal tablet according to claim 1, it is characterized in that hepatocyte growth-promoting factors not only comprises the HGF of the various molecular weight that extract and produce by genetic engineering from animal livers, also comprises the chemical modification body of acceptable HGF on the medicine.
8. hepatocyte growth-promoting factors buccal tablet according to claim 1 is characterized in that absorption enhancer, taste modifying agent and pH value buffer agent can exist simultaneously or not be present in the buccal tablet, also can be wherein a kind of being present in the buccal tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03143959 CN1579544A (en) | 2003-08-09 | 2003-08-09 | Sucking tablet for promoting liver cell to growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03143959 CN1579544A (en) | 2003-08-09 | 2003-08-09 | Sucking tablet for promoting liver cell to growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1579544A true CN1579544A (en) | 2005-02-16 |
Family
ID=34579555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03143959 Pending CN1579544A (en) | 2003-08-09 | 2003-08-09 | Sucking tablet for promoting liver cell to growth |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1579544A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008102849A1 (en) * | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Hgf preparation |
| CN103190557A (en) * | 2013-04-16 | 2013-07-10 | 缪为民 | Novel compound nutritional product with liver damage repairing efficacy |
| JP5265514B2 (en) * | 2007-02-22 | 2013-08-14 | クリングルファーマ株式会社 | HGF preparation |
| CN104095882A (en) * | 2014-08-05 | 2014-10-15 | 广东宏远集团药业有限公司 | Hepatocyte growth promoting factor granules and preparation method thereof |
| CN105961767A (en) * | 2016-07-07 | 2016-09-28 | 杭州华缔集团生物科技有限公司 | Chocolate as well as preparation method and application thereof |
-
2003
- 2003-08-09 CN CN 03143959 patent/CN1579544A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008102849A1 (en) * | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Hgf preparation |
| WO2008102452A1 (en) * | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Hgf preparation |
| EP2119449A4 (en) * | 2007-02-22 | 2013-05-08 | Kringle Pharma Inc | Hgf preparation |
| US8461112B2 (en) | 2007-02-22 | 2013-06-11 | Kringle Pharma Inc. | HGF preparation |
| JP5265514B2 (en) * | 2007-02-22 | 2013-08-14 | クリングルファーマ株式会社 | HGF preparation |
| CN103190557A (en) * | 2013-04-16 | 2013-07-10 | 缪为民 | Novel compound nutritional product with liver damage repairing efficacy |
| CN104095882A (en) * | 2014-08-05 | 2014-10-15 | 广东宏远集团药业有限公司 | Hepatocyte growth promoting factor granules and preparation method thereof |
| CN104095882B (en) * | 2014-08-05 | 2017-08-25 | 广东宏远集团药业有限公司 | A kind of PHGF particle and its manufacture method |
| CN105961767A (en) * | 2016-07-07 | 2016-09-28 | 杭州华缔集团生物科技有限公司 | Chocolate as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1030964C (en) | Taste-masking composition of bitter pharmaceutical agents | |
| EP1976562B1 (en) | Water-soluble films comprising low-viscosity alginates | |
| TWI548426B (en) | Diethylstilbestrol dosage form and methods of treatment | |
| CN101374503B (en) | Quickly disintegrating tablet produced by direct dry-tabletting | |
| CN1234230A (en) | Chewing article | |
| CN1281356A (en) | Quickly soluble solid preparations | |
| CN1915215A (en) | Oral cavity disintegration preparation | |
| US20070154549A1 (en) | Multiparticulate formulations for oral delivery | |
| CN102525903B (en) | Oral liquid preparation of pidotimod | |
| CN1939358A (en) | Sarcandra glaber dispersant tablets | |
| CN1742957A (en) | Sangju effervescent tablet for treating common cold | |
| JPWO2005084703A1 (en) | Sustained release oral composition | |
| CN1579544A (en) | Sucking tablet for promoting liver cell to growth | |
| CN1989960A (en) | Andrographolide dispersed tablet | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| JP5476782B2 (en) | Method for producing arginine-containing tablets | |
| CN1939449A (en) | Infantile heat-clearing and antitussive dispersing tablets | |
| CN1785179A (en) | Compounding chewable vitamin tablets and its prepn. method | |
| CN1939355A (en) | Ginkgo dispersing tablets | |
| CN101011385A (en) | Pharmaceutical composition of coumarin derivative and its preparation and application | |
| CN1957938A (en) | Effervescence tablet of Glucurolactone, and preparation method | |
| JP3197222B2 (en) | Powdery nasal composition | |
| CN1695734A (en) | Medication combination of kinase of fermented soybean in microcapsule, and preparation method | |
| CN1513550A (en) | Lozenge containing liver cell growth promoting agent and interferon | |
| CN1626143A (en) | Medication for treating pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060908 Address after: 32F, global Plaza, No. 54, 158, Fuzhou Applicant after: Guangshengtang pharmaceutical Industry Co., Ltd. Fujian Address before: Room 1, unit 10, building 36, No. two, 404 Road, Qingdao, Shandong, Anshan Applicant before: Yang Xihong |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |